RBC Capital analyst Simos Simeonidis said they would buy today's weakness in Immunogen Inc. (NASDAQ: IMGN), which they believe is ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE